SCHEMBL301718

SCHEMBL301718

NS(=O)(=O)c1ccc(F)c(F)c1

nearest known ligand 0.69

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
CA2 P00918 11/20 0.69
CA1 P00915 8/20 0.69
CA9 Q16790 4/20 0.69
CA12 O43570 1/20 0.69
CA4 P22748 1/20 0.69
CA6 P23280 1/20 0.69
CA5A P35218 1/20 0.69
CA7 P43166 1/20 0.69
CA14 Q9ULX7 1/20 0.69
CA5B Q9Y2D0 1/20 0.69
SOS1 Q07889 2/20 0.63
PTGS1 P23219 6/20 0.56
PTGS2 P35354 6/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28299345 0.98 CA2 (0.67) CA2CA1CA9CA12CA4
Thiophene SCHEMBL20502568 0.87 CA2 (0.55) CA2CA1CA9CA12CA4
SCHEMBL15068035 0.82 CA2 (0.61) CA2CA1CA9CA12CA4
SCHEMBL21430059 0.82 CA2 (0.70) CA2CA1CA9CA12CA4
SCHEMBL30291161 0.82 CA2 (1.00) CA2CA1CA9CA12CA4
SCHEMBL1179872 0.82 CA2 (1.00) CA2CA1CA9CA12CA4
SCHEMBL1512006 0.82 CA2 (0.64) CA2CA1CA9CA12CA4
SCHEMBL30291222 0.82 CA2 (0.64) CA2CA1CA9CA12CA4
SCHEMBL30291220 0.82 CA2 (0.64) CA2CA1CA9CA12CA4
SCHEMBL13885067 0.82 CA2 (0.59) CA2CA1CA9CA12CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 263 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119219810-A Ionic polymer and preparation method and application thereof 佛山绿动氢能科技有限公司 2024-12-31 CN claimed
WO-2024115549-A1 ARYL- AND HETEROARYL-SULFONAMIDE DERIVATIVES AS CCR8 MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2024-06-06 WO claimed
CN-114614058-B Thin-layer composite proton exchange membrane and preparation method and application thereof 中国石油化工股份有限公司 2024-05-07 CN claimed
US-11945784-B2 IRE1 small molecule inhibitors CORNELL UNIVERSITY (US) 2024-04-02 US claimed
CN-114914363-A Efficient and stable perovskite solar cell and preparation method thereof 西安电子科技大学 2022-08-16 CN claimed
CN-114614058-A Thin-layer composite proton exchange membrane and preparation method and application thereof 中国石油化工股份有限公司 2022-06-10 CN claimed
CN-114432903-A Composite membrane with acid resistance and preparation method and application thereof 中国石油化工股份有限公司 2022-05-06 CN claimed
CN-108963389-B Gelable system for lithium-air battery and preparation method and application thereof 北京师范大学 2020-11-13 CN claimed
EP-3637525-A1 FLEXIBLE ALL-SOLID-STATE LITHIUM-ION SECONDARY BATTERY AND MANUFACTURING METHOD THEREFOR Beijing Normal University (CN) 2020-04-15 EP claimed
EP-3637524-A1 GELATINIZED SYSTEM AND APPLICATIONS IN LITHIUM AIR BATTERY, SUPER CAPACITOR OR CAPACITOR BATTERY IN ORGANIC SYSTEM Beijing Normal University (CN) 2020-04-15 EP claimed
US-20200099090-A1 FLEXIBLE ALL-SOLID-STATE LITHIUM-ION SECONDARY BATTERY AND PREPARATION METHOD THEREOF BEIJING NORMAL UNIVERSITY (CN) 2020-03-26 US claimed
US-20200099097-A1 GELABLE SYSTEM AND USES THEREOF IN LITHIUM-AIR BATTERIES, ORGANIC SUPERCAPACITORS OR CAPACITOR BATTERIES BEIJING NORMAL UNIVERSITY (CN) 2020-03-26 US claimed
CN-105283454-B Quinazoline and azepine quinazoline as RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/MTOR access double inhibitor ASANA BIOSCIENCES, LLC (US) 2019-10-29 CN claimed
CN-109761944-A A kind of chrysin amide derivatives and preparation method thereof and medical usage 武汉翼博济生生物科技有限公司 2019-05-17 CN claimed
EP-2616440-A1 ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES Adamed sp. z o.o. (PL) 2013-07-24 EP claimed
WO-2012035123-A1 ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES ADAMED SP. Z O.O. (PL) 2012-03-22 WO claimed
JP-4851328-B2 2012-01-11 JP claimed
JP-2007506692-A 2007-03-22 JP claimed
EP-1670470-A1 PYRIDINE DERIVATIVES AND USE THEREOF AS UROTENSIN II ANTAGONISTS Actelion Pharmaceuticals Ltd. (CH) 2006-06-21 EP claimed
WO-2005030209-A1 PYRIDINE DERIVATIVES AND USE THEREOF AS UROTENSIN II ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2005-04-07 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11945784-B2 IRE1 small molecule inhibitors XBP1, ERN2, ERN1 CA2 4217/4885CA1 4652/4885CA9 4397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.